Brief: Zyversa Therapeutics Reports Second Quarter 2023 Corporate And Financial Results
21/08/2023 21:46
Aug 21 (Reuters) - Zyversa Therapeutics Inc ZVSA.O :
* ZYVERSA THERAPEUTICS REPORTS SECOND QUARTER 2023 CORPORATE
AND
FINANCIAL RESULTS
* ZYVERSA THERAPEUTICS INC - QTRLY LOSS PER SHARE $4.84
* ZYVERSA THERAPEUTICS INC- PLANS UNDERWAY TO INITIATE PHASE
2A
CLINICAL TRIAL IN PATIENTS WITH DKD, WITH INITIAL PATIENT
ENROLLMENT EXPECTED BY Q1 2024
Source text for Eikon: ID:nGNX1367dG
Further company coverage: ZVSA.O
(Reporting by Zaheer Kachwala)
((Zaheer.Kachwala@thomsonreuters.com;))
Recent news on Zyversa Therapeutics
See all newsBrief: ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million
Brief: ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity
Brief: Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation
Brief: ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100’S Development Status
Brief: Zyversa Therapeutics Files For Prospectus Related To Offer & Resale Of Up To 1.6 Million Shares Of Common Stock By Selling Stockholder - SEC Filing